UKRAINS'KYI VISNYK PSYKHONEVROLOHII

The Scientific and Practical Journal of Medicine
ISSN 2079-0325(p)
DOI 10.36927/2079-0325
Home » Archive of numbers » 2024 » Volume 32, issue 3 (120) » OPTIMIZATION OF THE APPROACHES TO THE CORRECTION OF THE POST-COVID SYNDROME IN CLINICAL PRACTICE

OPTIMIZATION OF THE APPROACHES TO THE CORRECTION OF THE POST-COVID SYNDROME IN CLINICAL PRACTICE

Authors

Type of Article

  • Scientific Article

In the Section

  • DIAGNOSTICS AND THERAPY OF MENTAL AND BEHAVIORAL DISORDERS

Key words

Index UDK:
  • 616-036.8+615.8

Abstract

  • The article analyzes the methods of optimizing approaches to the correction of post-COVID syndrome in clinical practice, based on interdisciplinary analysis and integration of modern scientific data. The clinical manifestations of COVID-19 and the post-COVID syndrome, in particular, their impact on the cardiovascular, nervous, immune, and endocrine systems are considered. The key mechanisms of virus pathogenesis, its interaction with cell receptors and the influence on the exacerbation of chronic diseases have been determined. The significance of a deep understanding of these processes for the development of effective methods of correction of conditions associated with post-COVID syndrome is substantiated. It has been found that the manifestation of post-COVID syndrome can last more than 12 weeks and manifest itself in the form of fatigue, dyspnea, generalized pain, chest pain, mental disorders, decreased concentration of attention, memory impairment, anxiety, loss of taste or smell, as well as disturbances sleep Given the multidisciplinary nature of the lesions, a comprehensive NICE protocol has been developed for the diagnosis, monitoring, and rehabilitation of patients with this syndrome, which has been scientifically proven. The effectiveness of pharmacotherapy has been proven, in particular the use of meldonium and citicoline, which affect energy metabolism and neuroprotection, which is critically important for optimizing the recovery of patients. The conclusions drawn emphasize that the study of the consequences of post-COVID syndrome and the development of strategies for its correction are a serious challenge for modern medicine. It is highlighted that taking into account the individual characteristics of patients, as well as a comprehensive approach to treatment, can significantly improve the quality of life of those suffering from the long-term consequences of COVID-19. It is emphasized the need to include in the therapy not only pharmacological, but also psychological and rehabilitation methods that can help restore not only the physical, but also the emotional and social condition of patients. In particular, the emphasis is on the importance of interdisciplinary cooperation between cardiologists, neurologists, psychologists, and rehabilitators in creating effective recovery programs for people with post-COVID syndrome.

Pages

  • 32-40

Year / Issue

Download PDF

Bibliography

1. Fesenkova V. Y., Drannik H. M., Driianska V. Ie. Doslidzhennia in vitro vplyvu preparativ Erbisol na produktsiiu interleikinu-2 ta γ-interferonu T-khelperamy I typu zdorovykh donoriv [In vitro study of the effect of Erbisol drugs on the production of interleukin-2 and γ-interferon by T-helper type I of healthy donors]. Laboratorna diahnostyka [Laboratory diagnosis]. 2003;2:37-40. (In Ukrainian).
2. Hyrina O.M., Vityk L.D., Romaniuk L.I. Optymizatsiia likuvannia khvorykh na polinoz shliakhom zastosuvannia preparatu Ekstra Erbisol [Optimizing the treatment of patients with pollinosis by using the drug Extra Erbisol]. Zbirnyk naukovykh prats spivrobitnykiv NMAPO im. P.L. Shupyka [Collection of scientific works of employees of P.L.Shupyk's NMAPO]. Kyiv, 2006;15, kn. 2. P. 206-211. (In Ukrainian).
3. Drannik H. M., Kurchenko A. I., Fesenkova V. I. Vyvchennia vplyvu preparativ klasu Erbisol na produktsiiu tsytokiniv mononuklearamy peryferychnoi krovi zdorovykh donoriv ta onkolohichnykh khvorykh [Study of the effect of drugs of the Erbisol class on the production of cytokines by peripheral blood mononuclear cells of healthy donors and cancer patients]. Visnyk farmakolohii ta farmatsii [Journal of Pharmacology and Pharmacy]. 2006;7:29-32. (In Ukrainian). https://erbisol.com.ua/wp-content/uploads/2018/03/publication-drannik2006-2.pdf.
4. Nemirovska N. V. Dynamika zmin imunolohichnoho statusu ta lipidnoho obminu u khvorykh na polinoz z kholesterozom zhovchnoho mikhura na foni likuvannia [Dynamics of changes in immunological status and lipid metabolism in patients with pollinosis with cholesterosis of the gallbladder against the background of treatment]. Astma ta alerhiia [Asthma and allergies]. 2013;1:50-54. (In Ukrainian).
5. Management of post-acute covid-19 in primary care /Greenhalgh T., Knight M., A’Court C. [et  al.]  // BMJ. 2020.370:m3026. DOI: 10.1136/bmj.m3026.
6. Persistent symptoms after COVID-19: qualitative studyof  114 “long COVID” patients and draft quality criteria forservices / Ladds E., Rushforth A., Wieringa S. [et al.] // BMCHealth Serv Res. 2020. 20, 1144. DOI: https://doi.org/10.1186/s12913-020-06001-y.
7. Bulut C. Epidemiology of COVID-19 / C. Bulut, Y. Kato  //Turk J Med Sci. 2020. 50(SI-1). P. 563—570. DOI: 10.3906/sag2004-172.
8. Cabler S.S. A cytokine circus with a viral ringleader: SARSCoV-2-Associated cytokine storm syndromes  / S.  S.  Cabler,A. R. French, A. Orvedahl // Trends Mol Med. 2020. Vol. 26 (12).P. 1078—1085. DOI: 10.1016/j.molmed.2020.09.012.
9. Chen Y. Emerging coronaviruses: Genomestructure, replication, andpathogenesis / Y. Chen, Q. Liu, D. Guo // J. Med.Virol. 2020. Vol. 92 (4). P. 418—423. DOI: 10.1002/jmv.25681.
10. Cardiac involvement in COVID-19 patients: Risk factors, predictors, and complications: A review / [Aghagoli G.,Gallo Marin B., Soliman L. B., Sellke F. W.] // J Card Surg. 2020.Vol. 35 (6). P. 1302—1305. DOI: 10.1111/jocs.14538.
11. Cardiovascular complications in  COVID19  / Long B.,Brady W.J., Koyfman A., Gottlieb M. // Am. J. Emerg. Med. 2020.Vol. 38 (7). P. 1504—1507. DOI: 10.1016/j.ajem.2020.04.048.
12. The emergence of SARS-CoV-2 variant (s) and its impacton the prevalence of COVID-19 cases in the Nabatieh Region,Lebanon / Noureddine F. Y., Chakkour M., El Roz A. [et al.] //Med. Sci. 2021. Vol. 9 (2). P. 40. DOI: 10.3390/medsci9020040.
13. Omicron escapes the majority of existing SARS-CoV-2neutralizing antibodies / Cao Y, Wang J, Jian F. [et al.] // Nature2022. Vol. 602 (7898). P. 657—663. DOI: 10.1038/s41586-021-04385-3.
14. Pérez-Abeledo M. SARS-CoV-2 variants, a still unfinishedstory] / M. Pérez-Abeledo, J. C. Sanz Moreno // Vacunas. 2021.Vol. 22 (3). Р. 173—179. DOI: 10.1016/j.vacun.2021.06.003.
15. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology / Rambaut A., Holmes E. C.,O’Toole Á. [et al.] // Nat. Microbiol. 2020. Vol. 5 (11). Р. 1403—1407. DOI: 10.1038/s41564-020-0770-5.
16. Choi J. Y. SARS-CoV-2 variants of concern / J. Y. Choi,D. M. Smith // Yonsei Med. J. 2021. Vol. 62 (11). P. 961—968.DOI: 10.3349/ymj.2021.62.11.961.
17. COVID-19 rapid guideline: managing the long-termeffects of COVID-19. URI: https://www.nice.org.uk/guidance/ng188/chapter/5-Management.
18. South A. M. COVID19, ACE2, and the cardiovascularconsequences  / South A.M., Diz  D.I., Chappell M.C.  // Am.J. Physiol. Heart Circ. Physiol. Published. 2020. Vol. 318, No. 5.DOI: 10.1152/ajpheart.00217.2020.
19. Снігир Н.  В.  Корекція ендотеліальної дисфункціїпри  ішемічній хворобі серця в  поєднанні з  цукровимдіабетом // Ліки України. 2016, № 3. С. 53—56.
20. Spike protein recognition of mammalian ACE2 predictsthe host range and an optimized ACE2 for SARS-CoV-2 infection Biochem  / [Luan J., Lu Y., Jin  X., Zhang L.]  // Biophys. Res. Commun. 2020. Vol. 526. Р.  165—169. DOI: 10.1016/j.bbrc.2020.03.047.
21. SARS‐CoV‐2 spike protein harnesses SNX27–mediatedendocytic recycling pathway / Zhao L., Zhong K., Zhao J. [etal.] // MedComm. 2021. Vol. 2 (4). Р. 798—809. DOI: 10.1002/mco2.92.
22. Batlle D. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? / D. Batlle,J. Wysocki, K. Satchell // Clin. Sci. 2020. Vol. 134 (5). Р. 543—545.DOI: 10.1042/CS20200163.
23. ACE2/ADAM17/TMPRSS2 interplay may be  the mainrisk factor for COVID-19 / [Zipeto D., Palmeira J. D. F., Argañaraz G. A., Argañaraz E. R.] // Front. Immunol. 2020. Vol. 11:576745.DOI: 10.3389/fimmu.2020.576745.
24. Maly, V. P., Asoyan, I. M., Sai, I. V., & Andrusovych, I. V. (2020). Patohenez koronavirusnoi infektsii COVID-19 [Pathogenesis of the COVID-19 coronavirus infection]. Infektsiini khvoroby [Infectious diseases], (3), 73–83. (In Ukrainian). DOI: https://doi.org/10.11603/1681-2727.2020.3.11555
25. Neurologic manifestations of hospitalized patients withcoronavirus disease. 2019 in Wuhan, China  / L.  Mao, H.  Jin,M. Wang [et al.] // JAMA, Neurology. 2020. Vol. 77(6). P. 683—690.DOI: 10.1001/jamaneurol.2020.1127.
26. Neurologic features in severe SARS-CoV-2 infection /Helms J., Kremer S., Merdji H. [et al.] // N. Engl. J. Med. 2020.Vol. 382. P. 2268—2270. DOI: 10.1056/NEJMc2008597.
27. Neuroinvasive and neurotropic human respiratorycoronaviruses: potential neurovirulent agents in  humans  /Desforges M., LeCoupanec A., Brison É. // Adv Exp Med Biol.2014. Vol. 807. Р. 75—96. DOI: 10.1007/978-81-322-1777-0_6.
28. Loneliness and social isolation as risk factors for coronaryheart disease and stroke: systematic review and meta-analysisof longitudinal observational studies / Valtorta N. K., Kanaan M.,Gilbody S. [et al.] // Heart. 2016. Vol. 102 (13). Р. 1009—1016. DOI: 10.1136/heartjnl-2015-308790.
29. Loneliness and social isolation as risk factors for mortality:a meta-analytic review / Holt-Lunstad J., Smith T. B., Baker M.[et al.] // Perspectives on Psychological Science. 2015. Vol. 10 (2).Р. 227—237. DOI: 10.1177/1745691614568352.
30. Patients with mental health disorders in the COVID19epidemic / H. Yao, J. H.  Chen, Y. F.  Xu // Lancet Psychiatry.2020. Vol. 7 (4). Р. e21. DOI: 10.1016/S2215-0366(20)30090-0.
31. The psychological impact of quarantine and how to reduce it: rapid review of the evidence / Brooks S. K., Webster R. K.,Smith L. E. [et al.] // Lancet. 2020. Vol. 395 (10227). Р. 912—920. DOI: 10.1016/S0140-6736(20)30460-8.
32. Plataras C. Effect of CDP-choline on brain acetylcholinesterase and Na+/K+-ATPase in adult rats / C. Plataras, S. Tsakiris,P. Angelogianni // Clin. Biochem. 2000. № 33. Р. 351—357. DOI: 10.1016/s0009-9120(00)00084-9.
33. Secades J. J. Citicoline: pharmacological and clinicalreview. Rev. Neurol. 2011. Vol. 52 (2). Р. 1-62. PMID: 21432836.
34. Cavendish J. J. Role of antiplatelet therapy in cardiovascular disease II: Ischemic stroke / J. J. Cavendish, S. C. Cramer, G. D. Graham // Curr Med Res Opin. 2004. Vol. 20 (11).Р. 1845—1849. DOI: 10.1185/030079904X10674.
35. Burchynskyi S. H. Kombinovana neiroprotektsiia pry khronichnii ishemii holovnoho mozku: tsili, zavdannia, instrumenty [Combined neuroprotection in chronic cerebral ischemia: goals, tasks, tools]. Mizhnarodnyi nevrolohichnyi zhurnal [Journal of Neurology]. 2020. No. 3. T. 16. P. 50-57. doi: 10.22141/2224- 0713.16.3.2020.203449. (In Ukrainian).
36. Analysis of therapeutic efficacy of citicoline in patientswith vertigo of central origin and vascular aetiology / [D. Petrova,D. Maslarov, I. Angelov, D. Zekin] // Am. J. Neuroprotec. Neuroregen. 2012. Vol. 4. P. 1—8. URI: 10.1166/ajnn.2012.1043.

Journal’s Indexing:

UKRAINS'KYI VISNYK PSYKHONEVROLOHII

The Scientific and Practical Journal of Medicine

ДУ «ІНПН імені
П.В. ВОЛОШИНА
НАМН УКРАЇНИ»